Abstract
As the prevalence of tobacco use has decreased, it has become clear that individuals with mental illness comprise a substantial portion of the remaining smokers. Seventy to eighty percent of patients with schizophrenia smoke and their smoking is established before their first psychotic episodes or the initiation of treatment. Many patients with schizophrenia, and approximately 50% of their first degree relatives have abnormalities in auditory sensory gating and / or smooth pursuit eye movements. These abnormalities are corrected by nicotine, and they appear to be transmitted as autosomal dominant traits. Evidence is accumulating that these abnormalities reflect genetic variations in nicotine receptor number and function, that may increase susceptibility for schizophrenia. Recent studies suggest that bupropion, added to treatment with an atypical antipsychotic, can enhance the likelihood of smoking cessation or reduction in patients with schizophrenia. The prevalence of smoking is also substantially increased among patients with bipolar disorder, perhaps especially so among those with psychotic features. Nicotine delivered by gum or transdermal patch can provide short term relief for exacerbations of Tourettes Syndrome, but its use is limited by frequent toxicity, primarily nausea.
Keywords: Schizophrenia, Bipolar disorder, Tourettes syndrome, nicotinic receptors
Current Drug Targets - CNS & Neurological Disorders
Title: The Importance of Nicotinic Acetylcholine Receptors in Schizophrenia, Bipolar Disorder and Tourettes Syndrome
Volume: 1 Issue: 4
Author(s): Joseph P. McEvoy and Trina B. Allen
Affiliation:
Keywords: Schizophrenia, Bipolar disorder, Tourettes syndrome, nicotinic receptors
Abstract: As the prevalence of tobacco use has decreased, it has become clear that individuals with mental illness comprise a substantial portion of the remaining smokers. Seventy to eighty percent of patients with schizophrenia smoke and their smoking is established before their first psychotic episodes or the initiation of treatment. Many patients with schizophrenia, and approximately 50% of their first degree relatives have abnormalities in auditory sensory gating and / or smooth pursuit eye movements. These abnormalities are corrected by nicotine, and they appear to be transmitted as autosomal dominant traits. Evidence is accumulating that these abnormalities reflect genetic variations in nicotine receptor number and function, that may increase susceptibility for schizophrenia. Recent studies suggest that bupropion, added to treatment with an atypical antipsychotic, can enhance the likelihood of smoking cessation or reduction in patients with schizophrenia. The prevalence of smoking is also substantially increased among patients with bipolar disorder, perhaps especially so among those with psychotic features. Nicotine delivered by gum or transdermal patch can provide short term relief for exacerbations of Tourettes Syndrome, but its use is limited by frequent toxicity, primarily nausea.
Export Options
About this article
Cite this article as:
McEvoy P. Joseph and Allen B. Trina, The Importance of Nicotinic Acetylcholine Receptors in Schizophrenia, Bipolar Disorder and Tourettes Syndrome, Current Drug Targets - CNS & Neurological Disorders 2002; 1 (4) . https://dx.doi.org/10.2174/1568007023339210
DOI https://dx.doi.org/10.2174/1568007023339210 |
Print ISSN 1568-007X |
Publisher Name Bentham Science Publisher |
Online ISSN 1568-007X |
Related Articles
-
AChE Inhibition-based Multi-target-directed Ligands, a Novel Pharmacological Approach for the Symptomatic and Disease-modifying Therapy of Alzheimer’s Disease
Current Neuropharmacology The Role of Infections in the Pathogenesis of Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy Radical Scavenging and Antioxidant Capacity of Serotonin
Current Bioactive Compounds Nature: A Substantial Source of Auspicious Substances with Acetylcholinesterase Inhibitory Action
Current Neuropharmacology Hold Onto Your Hat! - Handling the Roller Coaster Emotions of the College Application Process
Adolescent Psychiatry Quality Evaluation of English Mobile Applications for Gestational Diabetes: App Review using Mobile Application Rating Scale (MARS)
Current Diabetes Reviews Screening American Indian/Alaska Natives for Alcohol Abuse and Dependence in Medical Settings
Current Drug Abuse Reviews Comparative Account of Quality Management and Regulatory Aspects of Products with Health Claims: Existing Approaches and Future Challenges for Probiotics and Herbal Products
Applied Clinical Research, Clinical Trials and Regulatory Affairs KDS2010: A Potent Highly Selective and Reversible MAO-B Inhibitor for Alzheimer’s Disease
Combinatorial Chemistry & High Throughput Screening Blood-Brain Barrier Integrity and Glial Support: Mechanisms that can be Targeted for Novel Therapeutic Approaches in Stroke
Current Pharmaceutical Design Oxidation of Potassium Channels in Neurodegenerative Diseases: A Mini- Review
CNS & Neurological Disorders - Drug Targets Autophagy to the Rescue
Current Neurovascular Research Cannabinoids as Analgesic Agents: Evidence from In Vivo Studies
Current Neuropharmacology Genetic Association Analysis of NOS3 and Methamphetamine-Induced Psychosis Among Japanese
Current Neuropharmacology Phenolic Compounds from Plants as Nitric Oxide Production Inhibitors
Current Medicinal Chemistry Gender Difference Response of Male and Female Immunodeficiency Rats Treated with Tissue-specific Biomolecules
Current Pharmaceutical Biotechnology Computerized Methods in the Assessment and Prediction of Dementia
Current Alzheimer Research HIV-1 TAT and IMMUNE DYSREGULATION in AIDS PATHOGENESIS: a THERAPEUTIC TARGET
Current Drug Targets Endocannabinoid System in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Reduction in Estimated Glomerular Filtration Rate (eGFR) Results in an Increased Risk of Spontaneous Hemorrhagic Transformation in Patients with Large-artery Atherosclerosis Stroke
Current Neurovascular Research